<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739944</url>
  </required_header>
  <id_info>
    <org_study_id>RACC</org_study_id>
    <nct_id>NCT03739944</nct_id>
  </id_info>
  <brief_title>Different Surgical Approaches in Patients of Early-stage Cervical Cancer</brief_title>
  <official_title>Randomized Trial of Different Surgical Approaches in Patients of Chinese Early-stage Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, randomized controlled study aims to compare the survival outcomes
      (including overall survival, progression-free survival and disease-free survival between
      Chinese uterine cervical patients receiving different surgical routes (laparotomy and
      laparoscopy) for radical hysterectomy or trachelectomy, which is the primary study objective.
      All patients with uterine cervical cancer of FIGO stage IA1 (with lymphovascular space
      invasion), IA2 and IB1 will be included and randomized into two groups: laparotomy and
      laparoscopy groups for radical hysterectomy or trachelectomy. Secondary study objectives
      include: patterns of recurrence, treatment-associated morbidity (6 months from surgery),
      cost-effectiveness, pelvic floor function, and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2018</start_date>
  <completion_date type="Anticipated">November 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 23, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Five years</time_frame>
    <description>The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Five years</time_frame>
    <description>The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Five years</time_frame>
    <description>In cancer, the length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity rate</measure>
    <time_frame>Six months</time_frame>
    <description>Refers to having a disease or a symptom of disease, or to the amount of disease within a population. In this study, morbidity of six months from the surgery is defined according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost-effectiveness of different surgical routes</measure>
    <time_frame>One year</time_frame>
    <description>The direct cost of different surgical routes</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>Three years</time_frame>
    <description>The quality of life measured by academic questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Sex function</measure>
    <time_frame>Five years</time_frame>
    <description>Sex function measured by academic questionnaire before and after surgeries</description>
  </other_outcome>
  <other_outcome>
    <measure>Urodynamics</measure>
    <time_frame>Five years</time_frame>
    <description>Urinary functions are measured by dynamic tests before and after surgeries</description>
  </other_outcome>
  <other_outcome>
    <measure>Rectal functions</measure>
    <time_frame>Five years</time_frame>
    <description>Rectal functions are measured by dynamic tests before and after surgeries</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Uterine Cervical Neoplasm</condition>
  <condition>Laparotomy</condition>
  <condition>Laparoscopy</condition>
  <condition>Survival</condition>
  <condition>Mortality</condition>
  <condition>Morbidity</condition>
  <condition>Quality of Life</condition>
  <condition>Pelvic Floor Disorders</condition>
  <condition>Cost-Benefit Analysis</condition>
  <arm_group>
    <arm_group_label>Laparotomic radical hysterectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparotomic radical trachelectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic radical hysterectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic radical trachelectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparotomic radical hysterectomy</intervention_name>
    <description>Laparotomic radical hysterectomy for patients without fertility requirement</description>
    <arm_group_label>Laparotomic radical hysterectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparotomic radical trachelectomy</intervention_name>
    <description>Laparotomic radical hysterectomy for patients with fertility requirement</description>
    <arm_group_label>Laparotomic radical trachelectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic radical hysterectomy</intervention_name>
    <description>Laparoscopic radical hysterectomy for patients without fertility requirement</description>
    <arm_group_label>Laparoscopic radical hysterectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic radical trachelectomy</intervention_name>
    <description>Laparoscopic radical hysterectomy for patients with fertility requirement</description>
    <arm_group_label>Laparoscopic radical trachelectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed primary adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma
             of the uterine cervix

          -  FIGO stage IA1 (with lymphovascular space invasion), IA2 or IB1

          -  Type II or III radical hysterectomy or trachelectomy

          -  Performance status of ECOG 0-1

          -  Aged 18 years or older

          -  Signed an approved informed consents

        Exclusion Criteria:

          -  Not satisfying any of the inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>13911988831</phone>
    <phone_ext>86</phone_ext>
    <email>lileigh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>008613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>December 26, 2018</last_update_submitted>
  <last_update_submitted_qc>December 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Pelvic Floor Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be available to all the researches via public websites.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be available once the papers were accepted and be available for ever</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

